gemcitabine has been researched along with Leukemia P388 in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (66.67) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ahmad, I; Ahmad, MU; Ali, SM; Chen, P; Chien, PY; Khan, AR; Sheikh, S | 1 |
Amenitsch, H; Bourgaux, C; Couvreur, P; Desmaële, D; Lepêtre-Mouelhi, S; Mangenot, S; Ollivon, M; Pili, B; Poupaert, JH; Reddy, LH | 1 |
Gilbert, KS; Grindey, GB; Waud, WR; Worzalla, JF | 1 |
Marańda, E; Robak, T | 1 |
Marañda, E; Robak, T; Szmigielska, A | 1 |
Boder, GB; Grindey, GB; Hertel, LW; Kroin, JS; Poore, GA; Rinzel, SM; Todd, GC | 1 |
6 other study(ies) available for gemcitabine and Leukemia P388
Article | Year |
---|---|
In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate.
Topics: Animals; Antineoplastic Agents; Body Weight; Cardiolipins; Cell Proliferation; Deoxycytidine; Dipyridamole; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; HT29 Cells; Humans; Leukemia P388; Leukocyte Count; Mice; Mice, SCID; Neutropenia; Nucleoside Transport Proteins; Pancreatic Neoplasms; Thioinosine; Xenograft Model Antitumor Assays | 2006 |
Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue.
Topics: Animals; Antineoplastic Agents; Cryoelectron Microscopy; Deoxycytidine; Gemcitabine; Leukemia P388; Macromolecular Substances; Mice; Mice, Inbred DBA; Models, Molecular; Nanostructures; Nanotechnology; Scattering, Small Angle; Squalene; X-Ray Diffraction | 2008 |
Lack of in vivo crossresistance with gemcitabine against drug-resistant murine P388 leukemias.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Leukemia P388; Mice; Molecular Structure | 1996 |
Interactions of 2',2'-diflurodeoxycytidine (gemcitabine) with tumor necrosis factor alpha or its mutein VI in murine leukemias L1210 and P388.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Interactions; Gemcitabine; Leukemia L1210; Leukemia P388; Male; Mice; Tumor Necrosis Factor-alpha | 1998 |
Additive action of gemcitabine (2',2'-difluorodeoxycytidine) and 2-chlorodeoxyadenosine on murine leukemias L1210 and P388.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Leukemia L1210; Leukemia P388; Male; Mice | 1999 |
Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line; Cell Survival; Deoxycytidine; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Gemcitabine; Humans; Leukemia L1210; Leukemia P388; Leukemia, Experimental; Male; Mice; Mice, Inbred ICR; Mice, Inbred Strains; Neoplasms, Experimental; Tumor Cells, Cultured | 1990 |